DARA BioSciences to Present at Sidoti & Company 2011 Micro-Cap Conference
16. Dezember 2010 09:30 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Dec. 16, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that Richard A. Franco, Chief Executive Officer and President, is scheduled to present at the...
DARA BioSciences KRN5500 Reduces Allodynia in Patients With Neuropathic Pain
14. Dezember 2010 09:00 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Dec. 14, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today additional positive results from its successfully completed KRN5500 Phase 2a Clinical Study for...
DARA BioSciences to Present at the 14th Annual Biotech & Specialty Pharmaceuticals Industry Investor Conference of the New York Society of Security Analysts ("NYSSA")
15. November 2010 09:30 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Nov. 15, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a biopharmaceutical development company, today announced that the Company will present at the New York Society of...
NASDAQ Grants DARA's Request for Continued Listing
11. November 2010 08:30 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Nov. 11, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) today announced that a NASDAQ Listing Qualifications Panel (the "Panel") has granted the Company's request for an...
DARA BioSciences Announces Successful Completion of a Phase I Clinical Study of DB959 for the Treatment of Type 2 Diabetes
04. November 2010 08:30 ET
|
DARA BioSciences, Inc.
DB959 is a Highly Selective, Non-TZD
First-In-Class Dual PPAR-Delta/Gamma Agonist
DARA is Advancing Two Drugs From Its Portfolio Through Clinical Trials
RALEIGH, N.C., Nov. 4, 2010 (GLOBE...
DARA BioSciences Awarded Grants Totaling Approximately $500,000 for Its Two Drugs Advancing Through Clinical Studies
02. November 2010 08:30 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Nov. 2, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences (Nasdaq:DARA) announced today grant approvals by the Internal Revenue Service under the Patient Protection and Affordable Care Act of...
DARA BioSciences Signs Definitive Agreement to Raise $1.4 Million in Registered Direct Offering
25. Oktober 2010 08:30 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Oct. 25, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a development-stage pharmaceutical company, today announced that it has entered into a definitive agreement with...
DARA Announces Analytical Results in Efficacy and Dose Response of KRN5500 in Patients with Chemotherapy Induced Peripheral Neuropathy and Advanced Cancer
08. September 2010 10:00 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Sept. 8, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences (Nasdaq:DARA) announced today that it presented study results from its Phase 2 multicenter, placebo controlled, double-blind,...
DARA BioSciences to Present at Rodman & Renshaw Annual Global Investment Conference
01. September 2010 08:45 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Sept. 1, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that Richard A. Franco, R.Ph., Chief Executive Officer and President, is scheduled to present at...
DARA BioSciences Selected to Present at the 13th World Congress on Pain
20. August 2010 08:45 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Aug. 20, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that the company has been selected by the Scientific Program Committee to present at the Congress...